LIPID PHOSPHATASE ASSAYS IN DISEASE AND DRUG DISCOVERY

Information

  • Research Project
  • 6549062
  • ApplicationId
    6549062
  • Core Project Number
    R43DK062522
  • Full Project Number
    1R43DK062522-01
  • Serial Number
    62522
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/1/2002 - 22 years ago
  • Project End Date
    7/31/2003 - 21 years ago
  • Program Officer Name
    SONG, MIN-KYUNG H.
  • Budget Start Date
    8/1/2002 - 22 years ago
  • Budget End Date
    7/31/2003 - 21 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/29/2002 - 22 years ago

LIPID PHOSPHATASE ASSAYS IN DISEASE AND DRUG DISCOVERY

DESCRIPTION (provided by applicant): Phosphoinositide phosphates (PlPns) are important second messengers in signaling pathways controlling cellular proliferation, survival, morphology, and motility. Disruption of these pathways is common to many disease states, including diabetes, cardiovascular disease, and cancer. Because the activity of lipid second messengers is often determined by their phosphorylation state, the enzymes that act to modify these lipids are central to the correct execution of many signaling events. We propose to develop novel methods for the determination of phosphoinositide phosphatase activity. These assays will be aimed at measuring the activity of the lipid phosphatases PTEN, SHIP1, and SHIP2, which modulate phosphoinositide 3-kinase signaling by conversion of Pl (3,4,5) P3 to Pl (4,5) P2 and Pl(3,4)P2 respectively. These enzymes are important in signaling pathways that regulate insulin sensitivity and allergic and immune response, and which are often altered in carcinogenesis. Because signaling events involving these phsophoinositide phosphatases are often perturbed in disease progression, particularly non-insulin dependent diabetes mellitus (NIDDM) and cancer, these assays should have significant value as research and diagnostic tools as well as drug-screening platforms.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ECHELON BIOSCIENCES, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SALT LAKE CITY
  • Organization State
    UT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    84108
  • Organization District
    UNITED STATES